What is Intravacc?
Intravacc, situated at Utrecht Science Park Bilthoven in the Netherlands, operates as a prominent global contract development and manufacturing organization (CDMO). The company is dedicated to the innovation and production of vaccines targeting infectious diseases. Intravacc provides comprehensive expertise, guiding vaccine development from initial concept through to Phase I/II clinical studies for a diverse international clientele. Its focus on cutting-edge vaccine technology positions it as a key player in public health initiatives.
How much funding has Intravacc raised?
Intravacc has raised a total of $4.8M across 1 funding round:
Angel/Seed
$4.8M
Angel/Seed (2022): $4.8M with participation from Coalition for Epidemic Preparedness Innovations
Key Investors in Intravacc
Coalition for Epidemic Preparedness Innovations
The Coalition for Epidemic Preparedness Innovations (CEPI) is a foundation focused on financing research for vaccines against emerging infectious diseases, emphasizing equitable access during outbreaks. It was co-founded by major philanthropic and governmental entities.
What's next for Intravacc?
The substantial enterprise-level funding and recent strategic investment indicate Intravacc is poised for significant expansion and advancement in its vaccine development pipeline. This capital infusion is expected to accelerate research and development efforts, enhance manufacturing capacities, and potentially forge new partnerships. The company's trajectory suggests a strong commitment to addressing global health challenges through innovative vaccine solutions, solidifying its role as a critical CDMO in the biopharmaceutical landscape.
See full Intravacc company page
